Valiltramiprosate

Drug

Related News

Amyloid-Beta MAbs Offer Little Benefit in Alzheimer’s, but ALZ-801 Shows MCI Efficacy

Jul 31, 2026

A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.

APOE4 Gene Targeted in Multiple Alzheimer's Treatment Approaches

Apr 07, 2026

Multiple therapeutic approaches targeting the APOE4 gene are advancing, including small molecule drugs, gene therapies, and repurposed medications. The APOE4 variant confers a 60% lifetime Alzheimer's risk and affects brain metabolism, increasing seizure susceptibility. Research shows blood pressure drug terazosin can reduce seizures in APOE4 models by boosting cellular energy production.